Citigroup Begins Coverage on Mirum Pharmaceuticals (NASDAQ:MIRM)

Share on StockTwits

Citigroup started coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research note published on Monday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $21.00 price target on the stock.

Several other equities analysts have also issued reports on the stock. Guggenheim initiated coverage on shares of Mirum Pharmaceuticals in a report on Monday. They set a buy rating and a $18.00 price objective on the stock. Evercore ISI initiated coverage on shares of Mirum Pharmaceuticals in a report on Monday. They set an outperform rating and a $25.00 price objective on the stock. Five analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus target price of $25.00.

Shares of MIRM stock opened at $13.45 on Monday. Mirum Pharmaceuticals has a 52-week low of $12.05 and a 52-week high of $15.50.

In other news, Director Patrick J. Heron bought 450,000 shares of the stock in a transaction on Monday, July 22nd. The stock was bought at an average cost of $15.00 per share, for a total transaction of $6,750,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Holdings A/S Novo bought 575,000 shares of the stock in a transaction on Monday, July 22nd. The stock was purchased at an average price of $15.00 per share, with a total value of $8,625,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 1,357,000 shares of company stock valued at $20,355,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Recommended Story: What is Blockchain?

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lundin Mining Co.  Insider Nemesia S.a.r.l.  Acquires 150,000 Shares
Lundin Mining Co. Insider Nemesia S.a.r.l. Acquires 150,000 Shares
Brian B. Hansen Sells 15,000 Shares of Tandem Diabetes Care Inc  Stock
Brian B. Hansen Sells 15,000 Shares of Tandem Diabetes Care Inc Stock
Osisko gold royalties Ltd  Director Sells C$897,627.00 in Stock
Osisko gold royalties Ltd Director Sells C$897,627.00 in Stock
Deciphera Pharmaceuticals Inc  Director Sells $917,325.00 in Stock
Deciphera Pharmaceuticals Inc Director Sells $917,325.00 in Stock
Boston Advisors LLC Decreases Stock Holdings in Textron Inc.
Boston Advisors LLC Decreases Stock Holdings in Textron Inc.
Sumedh S. Thakar Sells 6,980 Shares of Qualys Inc  Stock
Sumedh S. Thakar Sells 6,980 Shares of Qualys Inc Stock


© 2006-2019 Ticker Report